---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Humanistic burden and health-related quality of life. Topics: Burden of disease in adults: multinational survey; Multinational adult survey: treatment exposure and quality-of-life outcomes; Health-related quality of life, depression, and work productivity: US patient survey; Anxiety and depression: health technology assessment background; 17 further topics. 21 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Burden of disease in adults: multinational survey

> “In the survey, participants reported 11.5 ± 14.2 HAE attacks (mean ± SD) in the past 6 months.”

Source: [Watt et al. (2026b)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-2"></a>

### Multinational adult survey: treatment exposure and quality-of-life outcomes

| Measure | Reported result |
| --- | --- |
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |

Source: [Watt et al. (2026b)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-3"></a>

### Health-related quality of life, depression, and work productivity: US patient survey

> “A total of 457 HAE patients responded to the survey (response rate, ∼19%).”
> “Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001).”
> “HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology.”
> “Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment.”
> “Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days.”

Source: [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/)

<a id="topic-2.2.1.8.1-4"></a>

### Anxiety and depression: health technology assessment background

> “Studies have shown that almost three-quarters of HAE patients noted that the disease had a significant impact on their quality of life, including anxiety (15% of patients) and depression (almost 40% of patients) related to their ability to carry out daily activities, fear of attacks, and concerns about transmission of the condition to their children.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.1.8.1-5"></a>

### Quality of life with subcutaneous prophylaxis compared with on-demand treatment alone: US patient survey

> “The greatest improvement in QoL was seen in patients who used novel SC prophylactic therapies, with a 59.5% (p < 0.01) improvement in median impairment scores versus on-demand–only treatment.”
> “In addition, patients who used novel SC prophylactic therapies reported a 77% reduction in the number of attacks each year when compared with those who used on-demand–only treatment.”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.1-6"></a>

### Burden despite current therapies: US adult survey

> “A web-based survey was conducted from March to April 2025 among 100 US adults with HAE-C1INH currently receiving long-term prophylaxis and/or on-demand therapies.”
> “Even with treatment, 80% of respondents reported ≥1 HAE attack in the past year and 61% thought about HAE at least weekly.”
> “Mental health was the aspect that respondents felt was most impacted by HAE (54% of respondents), and 73% reported taking ≥2 measures to avoid attack triggers.”
> “Several concerns impacted the ability to reach normalization; lifetime use of medication was the most commonly reported concern (68% of respondents).”
> “The greatest unmet needs associated with long-term prophylaxis were cost- and access-related.”

Source: [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/)

<a id="topic-2.2.1.8.1-7"></a>

### Preferences for long-term prophylaxis and willingness to switch: US adult survey

> “A total of 150 individuals completed the survey.”
> “Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes.”
> “Route of administration and convenience were more than twice as important as dosing frequency.”
> “Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%).”
> “Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.”

Source: [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)

<a id="topic-2.2.1.8.1-8"></a>

### Health-related quality of life during the last treated attack by time to on-demand treatment: US patient survey

> “Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.”
> “A total of 94 respondents were included in the Treated Cohort, and 20 were included in the Untreated Cohort.”
> “In the Treated Cohort, the mean (SD) EQ-5D-5L index score was 0.849 (0.2) “Today” and 0.568 (0.3) “During the last treated attack” (Fig. 1A), with the latter score indicative of substantial impairment in HRQoL.”
> “The mean (SD) index score was 0.667 (0.3) in patients who treated <1 h of attack onset and 0.504 (0.3) in those who treated 5 to < 8 h of attack onset (Fig. 1B).”
> “In terms of administration route, reductions in HRQoL and work productivity and increases in activity impairment were generally more pronounced among IV OD users than among SC OD users (mean EQ-5D-5L index score “During the last treated attack”: 0.480 vs 0.615).”
> “Consistent with this, IV OD users took longer to administer treatment following attack onset than SC OD users (mean: 5.8 vs 2.8 h).”
> “Funding for Outcomes Insights was provided by KalVista Pharmaceuticals (Cambridge, MA, USA).”

Source: [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/)

<a id="topic-2.2.1.8.1-9"></a>

### Work productivity and activity impairment after a treated attack: US patient survey

> “Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.”
> “In the Treated Cohort, the mean value for attack-related activity impairment was 38% (Fig. 4).”
> “In the 7 days following attack onset, the average rates of absenteeism (work missed due to HAE), presenteeism (impairment while working due to HAE), and overall work impairment were 15%, 35%, and 39%, respectively.”
> “For respondents with “Mild,” “Moderate,” and “Severe” attacks, the mean level of absenteeism was 5%, 16%, and 35%; the mean level of presenteeism was 29%, 32%, and 68%; and mean overall work impairment was 32%, 36%, and 75%, respectively.”

Source: [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/)

<a id="topic-2.2.1.8.1-10"></a>

### Treatment-related anxiety and delay of on-demand treatment: US patient survey

> “Patients with HAE (type I or II) aged 12 years or older with more than or equal to 1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association.”
> “In the Treated Cohort (n = 94), of the 67% who reported treating their attack early, only 26% administered OD in less than 1 hour.”
> “Furthermore, 79% (n = 74) reported treatment-related anxiety, which correlated with treatment delay.”
> “Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).”
> “Untreated attacks lasted a mean of 2.3 days.”

Source: [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/)

<a id="topic-2.2.1.8.1-11"></a>

### Attack-related anxiety in a randomized on-demand treatment trial: KONFIDENT

> “Participants in the randomised, double‐blind, phase 3 KONFIDENT trial (NCT05259917) treated attacks with sebetralstat 300 mg, 600 mg or placebo as early as possible after onset.”
> “The full analysis set included 264 attacks.”
> “Overall, 115 (44%) of the attacks were rated as inducing moderate‐to‐extreme anxiety (i.e., GA‐NRS ≥ 4) at treatment administration (Table 1 and Table S1).”
> “Female sex, shorter time since HAE diagnosis and greater attack severity were associated with greater anxiety at treatment administration.”
> “This study was sponsored by KalVista Pharmaceuticals.”

Source: [Craig et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327167/)

<a id="topic-2.2.1.8.1-12"></a>

### Burden of injectable on-demand treatment: US and UK patient and caregiver interviews

> “The 25 study participants from the US and UK (17 patients; 8 caregivers), who completed the interview, highlighted emotional and logistical reasons for delaying or forgoing injectable on-demand treatment, including fear of needles, portability, and complexity of administration.”
> “Participants reported a dislike of needles, pain associated with injection of the medicine, and the need to go to a hospital or medical center as treatment-related reasons for delaying or opting not to treat an attack.”
> “The majority of participants (80%) reported not treating every attack; all participants described delaying treatment intentionally or unintentionally at least once.”
> “All participants expressed interest in an oral on-demand treatment for reasons including portability, pain-free administration, and ability to treat attacks earlier.”
> “The study was supported by KalVista Pharmaceuticals.”

Source: [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.1.8.1-13"></a>

### Carrying, delaying, and not treating attacks with on-demand treatment: US patient survey

> “People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete a 20-minute online survey between September 6, and October 19, 2022.”
> “Respondents included 107 people with HAE, 80% female, 98% adults (≥ 18 years).”
> “Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home.”
> “The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).”
> “Overall, 86% of respondents reported delaying on-demand treatment, despite recognizing the initial onset of an HAE attack and despite 97% of patients agreeing that it is important to recover quickly from an HAE attack.”
> “On average, one of every five (20%) HAE attacks are untreated (24% amongst on-demand only patients; 15% amongst prophylaxis patients).”
> “This work was sponsored by KalVista Pharmaceuticals.”

Source: [Betschel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271048/)

<a id="topic-2.2.1.8.1-14"></a>

### Administration-site adverse drug reactions with parenteral on-demand treatments: FDA Adverse Event Reporting System

> “We searched the FAERS database from October 1, 2009, to March 31, 2022, for reports of all FDA-approved on-demand therapies for HAE: plasma-derived C1-inhibitor (pdC1-INH), ecallantide, icatibant, and recombinant C1-inhibitor (rhC1-INH).”
> “The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year).”
> “Conclusion: Real-world data from FAERS were generally consistent with adverse events reported in clinical trials and suggest that patients experience substantial treatment burden associated with FDA-approved parenteral on-demand therapies for HAE attacks.”
> “It should be noted that ADR rates are not exposure adjusted and are based on spontaneous reporting.”

Source: [Tachdjian et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993116/)

<a id="topic-2.2.1.8.1-15"></a>

### Utility weights during and between attacks: European patient survey mapped to EQ-5D

> “Survey items that overlapped conceptually with the EuroQol 5-Dimensions (EQ-5D) domains (pain/discomfort, mobility, self-care, usual activities, and anxiety/depression) were manually crosswalked to the corresponding UK population-based EQ-5D utility weights.”
> “Overall, a total of 111 HAE-BOIS-Europe participants completed all selected survey items and thus allowed for computation of EQ-5D-based utilities.”
> “The mean utilities for an HAE attack and between attacks were 0.44 and 0.72, respectively.”
> “Utilities for an acute attack were dependent on the severity of pain of the last attack (0.61 for no pain or mild pain, 0.47 for moderate pain, and 0.08 for severe pain).”

Source: [Aygören-Pürsün et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5019462/)

<a id="topic-2.2.1.8.1-16"></a>

### Time trade-off utilities by attack location: general public valuation in England

> “Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.”
> “TTO analysis was based on vignette valuation completed by 100 members of the general public.”
> “The TTO values were as follows: attack-free, 0.783 (standard deviation [SD] 0.316); hand: 0.582 (SD 0.380); facial: 0.483 (SD 0.448); abdominal: 0.345 (SD 0.458); and laryngeal: 0.128 (SD 0.529).”
> “This study was funded by BioCryst Pharmaceuticals, Inc.”

Source: [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)

<a id="topic-2.2.1.8.1-17"></a>

### Utility weights with and without attack symptoms drawn from the literature for an economic model

> “Utility values were drawn from the literature”
> “citing a utility of 0.51 when experiencing attack symptoms and 0.83 without symptoms.”
> “Nonattack baseline utility and attack utility were implemented for effectiveness calculations; time to attack resolution was considered as well.”

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/)

<a id="topic-2.2.1.8.1-18"></a>

### EQ-5D-5L utility and its decrement during an attack: Dutch patient survey

> “Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.”
> “The response rate was 78% (69 of 88).”
> “The mean quality of life in the entire sample was 30.99 as expressed by the AE-QoL and 0.873 as expressed by the EQ-5D-5L utility value.”
> “Utilities dropped by 0.320 points during an angioedema attack.”

Source: [Fijen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36990433/)

<a id="topic-2.2.1.8.1-19"></a>

### Patient-defined attack severity and EQ-5D-5L by attack location: US qualitative study for economic evaluation

> “Semi-structured qualitative interviews were conducted with US adults with HAE, purposively sampled with quotas for attack severity and attack locations.”
> “A total of 25 adults with HAE took part in the interviews.”
> “The results indicate that HRQoL is only slightly impaired by a mild attack compared to in-between attacks, however a severe attack has a considerable impact on HRQoL.”
> “The lowest utility value in the TTO study was 0.128 for a laryngeal attack, which is higher than the lowest values reported in this study (0.03, throat attack and 0.06 abdominal attack).”
> “This study was funded by Ionis Pharmaceuticals.”

Source: [Gallop et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2740956)

<a id="topic-2.2.1.8.1-20"></a>

### Physician-reported attainment of treatment goals: international physician survey

> “Of 64 respondents from 32 countries, most (91%) had > 5 years of experience in managing HAE.”
> “Overall, 48% of respondents (n = 31/64) reported that < 50% of their patients had achieved the WAO/EAACI HAE treatment goals of total disease control and “normalization” of life at the time of the survey.”
> “Burden of disease remains a challenge among patients, as reported by their physicians.”
> “This study was funded by CSL Behring.”

Source: [Buttgereit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12306030/)

<a id="topic-2.2.1.8.1-21"></a>

### Attacks, on-demand treatment, anxiety, and depression: multinational patient survey

> “We conducted a noninterventional, cross-sectional, web-based survey of patients with a self-reported diagnosis of HAE type 1/2 in Australia, Austria, Canada, France, Germany, Spain, Switzerland, and the United Kingdom to gain a comprehensive real-world understanding of the characteristics of HAE and its burden from the perspective of the patient.”
> “A total of 242 patients (67.4% female; mean [range] age 43.8 [18–92] years) completed the survey.”
> “Patients reported a mean (SD) of 12.5 (14.1) attacks in the past 6 months.”
> “The most recent attack occurred within the past month in 79.7% of patients; most were of moderate severity, 6.6% affected the larynx, 21.9% lasted ≥ 3 days, and 76.4% were treated with on-demand medication.”
> “Moderate to severe anxiety and depression were reported in 38.0% and 17.4% of patients, respectively, as measured using the HADS.”

Source: [Mendivil et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7893968/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
